NASDAQ: NKGen - “SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients”
Confident in the NK tech, looking forward to phase 1 from ALA, outlook is positive.
Ann: Arovella Completes $12.5M Placement - Funded to Phase 1 Data, page-7
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $136.5M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.3¢ | $193.6K | 1.540M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13730 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 727520 | 7 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| ALA (ASX) Chart |